Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 343

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 343
---
 placed in Administration.

The Directors have
prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period 12 months
from the date of approval of this interim financial information. These forecasts show that further financing will be required before the
first quarter of 2025 assuming, inter alia, that certain development programs and other operating activities continue as currently planned.
If we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our
existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our ordinary shares
(including the ADSs) and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights
and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly
harm our business, financial condition and prospects.

| F-6 |

On August 27, 2024,
the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising that the Company
was not in compliance with the minimum bid requirement set forth in NASDAQ’s rules for continued listing of its securities. The
Company has requested a Hearing Panel which has paused any suspension or delisting action pending the hearing. If the Company's ADSs are
delisted, it could be more difficult to buy or sell the Company's ADSs or to obtain accurate quotations, and the price of the Company's
ADSs could suffer a material decline. Delisting may impair the Company's ability to raise capital.

In the Directors’
opinion, the environment for financing of small and micro-cap biotech companies continues to be challenging. While this may present acquisition
and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa
are likely to be dilutive. The Directors continue to evaluate financing options, including those connected to acquisitions and/or mergers,
potentially available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there
can be no assurance that any of alternative courses of action to finance the Group would be successful. This requirement for additional
financing in the short term represents a material uncertainty that may cast significant doubt upon the Group’s ability to continue
as a going concern. Should it become evident in